SOEDAK2009 --- PREPARE FOR THE LONG RUN

TABLE: Inhalte   Printer Friendly

 Search
  Show all  Advanced Search 
    

First  Previous  1  2  3  4  5  6  7  8  9  10  11-15  Next  Last       Records 121 to 140 of 285
Titel (*)
Autor (*)
 
HBV genotype diversity in HIV/HBV co-infected patients in the Swiss HIV cohort
Florian Bihl1, Gladys Martinetti2, Bruno Ledergeber3, Sandrine Estoppey Younes4, Rainer Weber3, Pietro Vernazza5, Manuel Battegay6, Hans Jakob Furrer7,
View
Switching to raltegravir in HIV-infected patients with well controlled viral load - efficacy and safety
Stefan Mauss1, Ana Milincovic2, Florian Berger1, Julia Henke1, Guenther Schmutz1, Petra Hegener1, Dieter Kuschak3, Stephan Schauseil3, Jospe Mallolas
View
HIV integrase inhibition - more complex that simply blocking one key viral enzyme function
Séverine Louvel1, François Hamy2, Thomas KIimkait1
View
New antiretroviral treatment options with integrase-inhibitors, CCR5-antagonists and second-generation-NNRTI and combination antiretroviral therapy (cART) in the ClinSurv cohort
Barbara Bartmeyer1, Kollan Christian1, Kühne Andrea1, Osamah Hamouda1, Studiengruppe Klinische Surveillance ClinSurv
View
Final results from the Connect cohort confirm efficacy and safety of enfuvirtide in a "real life setting "
Olaf Degen1, Gerd Faetkenheuer2, J Bogner3, S Dupke4, S Koeppe5, S Gute6, W Becker7, A Tappe8, Egbert Wellmann8, Hans-Juergen Stellbrink
View
Treatment of HIV-infected patients with a HAART regimen containing Enfuvirtide and a “second generation” protease inhibitor
Thore Lorenzen1, Irene Walther1, Johannes R. Bogner2, Jan van Lunzen3, Christoph Schuler4, Gerd Fätkenheuer5, Peter Gute6, Carl-Knut Schewe7, Siegfr
View
Opportunities to assessan optimized salvage regimen in HIV infected triple-class experienced patients by the expert advice system RADATA
Thore Lorenzen1, Irene Walther1, Peter Gute2, Johannes R. Bogner3, Stefan Mauss4, Matthias Stoll5, Heribert Knechten6, Jürgen Rockstroh7, Jan van L
View
Maraviroc in clinical practice - 24 weeks data
Heribert Knechten1, Christian Höhn1, Robert Ehret1, Frank Wiesmann1, Martin Hower2, Stefan Scholten3, Anton Neuwirth4, Wolfgang Köthemann4, Pa
View
Durable efficacy and safety of etravirine in treatment-experienced, HIV-1-infected patients: pooled Week-96 results from the phase-III DUET-1 and DUET-2 trials
J Vingerhoets1, B Woodfall1
View
Safety and efficacy of tenofovir DF (TDF) in combination with 3TC and efavirenz (EFV) in antiretroviral-naïve patients through seven years
Isabel Cassetti1, Jose Valdez R. Madruga2, Arnaldo Etzel3, Jamal Muhamad A.H. Suleiman4, Britta Ranneberg5, Lijie Zhong6, Andrew Cheng6, Jeffrey Enejosa6,
View
The 48-week efficacy and safety of switching to fixed dose efavirenz/emtricitabine/tenofovir DF in HIV-1-infected patients receiving HAART
Edwin De Jesus1, Anton Pozniak2, Markus Bickel3, Joel Gallant4, Jose Arribas5, Yun Zhou6, Andrew Cheng6, Jeffrey Enejosa6
View
Simplification of therapy (ART) with Efavirenz/Emtricitabine/Tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patients
B. Young1, E. de Jesus2, J.O. Morales-Ramirez3, Tina Nakonz4, J-F. Maa5, D. Seekins5, A. Farajallah5, R. Ebrahimi6, J. Flaherty6
View
Safety and tolerability of etravirine (ETR) in hepatitis B and/or C co-infected patients in DUET-1 and 2: 48 week results
Albrecht Stoehr1, Gerd Fätkenheuer2, Klaus Göbels3, Frank-Detlef Goebel4, Hans Jäger5, Arend Moll6, Jürgen Kurt Rockstroh7, Dieter Schuster
View
Langzeitverträglichkeit und -effizienz von Nevirapin als Bestandteil einer HAART
Ivanka Krznaric1, Stephan Dupke1
View
Patient reported outcomes after simplification to a single tablet regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF)
S. Hodder1, K. Mounzer2, E. de Jesus3, Tina Nakonz4, K. Grimm5, A. Farajallah5, J. Flaherty6
View
Safety and efficacy of tenofovir in pregnant women
Annette Elisabeth Haberl1, Richard Linde2, Anke Reitter3, Peter Gute4, Gaby Knecht4, Manfred Mösch5, Tessa Lennemann6, Gabriele Nisius6, Christoph
View
Kivexa versus Truvada: similar virological outcomes in ART-naïve patients starting a lopinavir/ritonavir-based regimen. 48-week-data from the STAR and STELLA cohorts
Eva Wolf1, Axel Baumgarten2, Bernhard Bieniek3, Stefanie Holm4, Martin Hower5, Hans Jaeger6, Thomas Lutz7, Markus Mueller8, Wolfgang Schmidt9
View
Efficacy and safety of TDF/FTC-containing first line HAART in clinical practice - two year data from the German outpatient cohort
Jan van Lunzen1, Gerd Fätkenheuer2, Thomas Lutz3, Stephan Klauke4, Stefan Mauss5, Carl Knud Schewe6, Heribert Knechten7, Patrick Braun7, Lothar Ga
View
Gutes Ansprechen einer Kombinationstherapie von Trizivir/Tenofovir bei Vorbehandelten über 96 Wochen. CTP-Score vs.1.2 als prädiktives Tool für den Therapieerfolg
Stephan Dupke1, Bettina Hintsche1, Christoph Mayr1, Frank Schlote1, Arend Moll1, Felise Krauthausen1, Daniel Prziwara1, Dorothea Schleehauf1, Siegfried
View
48-wk safety and efficacy of darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents in DELPHI
P Vis1, V Sekar1, B Van Baelen1, S Spinosa-Guzman1
View